As­traZeneca and Avil­lion win ap­proval for new asth­ma res­cue treat­ment in adults

As­traZeneca and Avil­lion un­sur­pris­ing­ly pulled a win on Wednes­day for Air­supra in adults, months af­ter an FDA ad­vi­so­ry com­mit­tee vot­ed over­whelm­ing­ly in sup­port of the new asth­ma res­cue treat­ment.

How­ev­er, the part­ners weren’t able to se­cure a nod in ado­les­cents and kids.

Air­supra, for­mer­ly known as PT027, is an in­haler com­bin­ing the two ex­ist­ing com­pounds al­buterol, a short-act­ing be­ta2-ag­o­nist (SA­BA), and budes­onide, an in­haled cor­ti­cos­teroid (ICS). While asth­ma pa­tients pre­vi­ous­ly had op­tions that con­tained ei­ther a SA­BA or an ICS, there were none that com­bined both com­po­nents for a bron­chodila­to­ry and an­ti-in­flam­ma­to­ry ef­fect.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER